Perez Daniel Antonio

CEO Perez liquidates 150k shares worth $8.3M in two-day sprint; stock rebounding strongly but near CEO's recent exit points.

Perez Daniel Antonio, Hinge Health's CEO and co-founder, executed a full liquidation of 150,000 shares across two trading days, raising approximately $8.3 million. The trades were structured as conversions followed by immediate sales at prices near current levels, with no net change to his holdings—a pattern consistent with options exercise and systematic disposition. Notably, this contrasts sharply with his track record: over the prior year, Perez had completed five sales at this ticker, and four of those five timing decisions proved sound as the stock fell after each exit—only one prior sale was poorly timed when the stock subsequently rose. However, the current sale occurs as the stock has rallied substantially and now trades well below its recent highs, suggesting he is exiting into a period of strength. The company's fundamentals remain mixed: while the latest quarter showed net profitability and revenue is growing robustly year-over-year, the full-year earnings remain deeply negative. This is Perez's first open-market sale after extending his tenure; prior transactions were equity compensation rollovers. The sale's scale and complete liquidation, combined with his historically accurate sell timing, warrants scrutiny regarding any underlying concerns, though the stock's recent strength tempers the bearish signal.

CEO Perez converts 166.7K derivative shares into common and sells entire converted batch at $40.26 for $6.7M

Perez Daniel Antonio, CEO & Co-Founder, converted 166,665 shares of common stock (derived from derivative securities) and immediately sold the full converted batch at $40.26 on 2026-02-12 for a total value of $6,710,516.23. This marks a derivative-conversion transaction, not a traditional open-market liquidation; the insider's actual position may remain held in other derivative instruments not yet reflected in our database. However, the post-conversion sale is notable: at the time of sale, the stock was trading at $40.26, but has since declined to $38.94 (current price), placing the transaction 30 days ago with a -10.1% subsequent price move and -35.7% from the 52-week high of $60.55. Perez's prior four sales at this ticker show consistent post-sale declines (ranging -10.7% to -28.9% over 30 days), establishing a pattern of selling into weakness. The company is generating significant revenue ($154.2M latest quarter) but remains unprofitable (net income -$1.8M), which may factor into the timing of this derivative conversion and sale.

CEO Perez sells 166.7K shares for $7.7M on derivative conversion; 100% stake liquidation of underlying common

Perez Daniel Antonio (CEO & Co-Founder) executed 2 separate sales on 2026-01-05 totaling 166,665 shares for $7,730,617.27 at a blended average price of $46.38. The Form 4 indicates this is a DERIVATIVE-CONVERSION transaction—the shares sold represent the settlement or exercise of derivative securities, not a discretionary open-market disposal. His post-transaction holding in the underlying common equity is now 0 shares. While the flag prohibits characterizing this as a full exit, the conversion mechanics mean his direct common equity stake has been fully converted. Current stock price of $48.83 is above the transaction's blended average of $46.38, reflecting a $2.45 per-share spread that reversed into the current market. The company is modestly profitable on a net-loss basis (revenue $154,211,000.00 versus net income $-1,844,000.00), providing limited earnings momentum to underpin valuation. The stock is trading 19.4% below its 52-week high, and Perez had executed another 2 sales of the same ticker on 2025-12-15 (outcomes not yet measurable). This derivative settlement, combined with recent prior activity, warrants scrutiny of insider confidence signals and forward guidance.

CEO Perez sold 166,670 shares for $8,088,310.28 across 2 transactions on 2025-12-15 at blended avg $48.53

CEO & Co-Founder Daniel Antonio Perez executed 2 separate sales totaling 166,670 shares for $8,088,310.28 on 2025-12-15, reducing his shareholding by 100% from the reported Table I position. The sales occurred at a blended average price of $48.53, slightly above the current price of $48.41. While the DERIVATIVE HOLDINGS flag indicates that Table I does not capture his complete position (derivative securities in Table II are not yet populated in the database), this filing reveals a significant reduction in his direct share holdings. At the company level, Hinge Health reported latest quarterly revenue of $154,211,000.00 against a net loss of $1,844,000.00, with the stock trading 20.0% below its 52-week high of $60.55. The transaction price relative to recent trading ranges and fundamentals provides data for assessing the signal this sale sends about insider confidence.